Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150250 · ClinicalTrials.gov registry record · Phase 2
Cholera Anti-Secretory Treatment Trial
A Phase 2 study, sponsored by PATH.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT04150250: Completed Phase 2 study, sponsored by PATH.
NCT04150250 is a Phase 2 study that has completed, run by PATH. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04150250, a Phase 2 study, has completed, sponsored by PATH.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This trial was designed to assess safety and preliminary efficacy of oral doses of iOWH032 on diarrhea output and clinical symptoms after a cholera challenge in healthy adult participants.
Primary Outcome
Diarrheal stool output rate is defined as the total volume of diarrheal stools (in mL, Grade 3 and above) divided by the number of hours between initiation of study drug (iOWH032 or placebo) and initiation of antibiotic therapy. Stools were graded based on consistency as follows: * Grade 1 - well formed (normal stool, does not take the shape of the container) * Grade 2 - soft (normal stool, does not take the shape of the container) * Grade 3 - thick liquid (diarrhea, takes the shape of the con
Interventions
- DRUG Placebo
- DRUG Antibiotics
- DRUG iOWH032
- OTHER V. cholerae Challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2020-07-27 |
| Phase | Phase 2 |
What the finished NCT04150250 record still lists
NCT04150250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04150250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04150250 about?
NCT04150250 is a clinical study titled "Cholera Anti-Secretory Treatment Trial". This trial was designed to assess safety and preliminary efficacy of oral doses of iOWH032 on diarrhea output and clinical symptoms after a cholera challenge in healthy adult participants.
What is the current status of trial NCT04150250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2019-11-04. Estimated completion is 2020-07-27.
What interventions are being tested in trial NCT04150250?
The interventions under investigation include: Placebo (DRUG), Antibiotics (DRUG), iOWH032 (DRUG), V. cholerae Challenge (OTHER).
Who is sponsoring clinical trial NCT04150250?
This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04150250's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI